Breakthrough Breakthrough Technology Technology

for afor aBrighter Future Brighter Future

Oramed Pharmaceuticals

OTC Bulletin Board: ORMP

Company with oral drug delivery platform

Based on over 25 years of medical research at Hadassah University Medical Center - Jerusalem

World leading scientific team

Experienced management team

Diverse product pipeline

Oral Insulin (ORMD 0801): Flag Ship Product

Oramed’s Delivery Platform

Normal digestion involves degradation of proteins/peptides

Breakdown by acidic pH of stomach + digestive enzymes

Oramed’s patent-pending technology platform is designed to

protect and ferry proteins to target in its intact and biologically active form.

enhances a protein's absorption through the gut wall into the bloodstream

Oral Insulin

Oral insulin is the only delivery system that mimics the biological and physiological processes

With an oral delivery system, insulin can become an earlier treatment modality with higher compliance

History of Development – Oral Insulin – ORMD 0801

2007

2008

Company established March 2006

Successful pre-clinical results April 2006

Swiss Caps agreementOctober 2006

Phase 1A trials August 2007

IND filingExpected4th Quarter 2009

2009

Phase 1B trialsMarch 2008

Phase 2A August 2008

IRB Approval Phase 2B(South-Africa)September 2008

Phase 2B trials

May 2009

Oramed’s Product Pipeline

Oral InsulinPhase 2a trials completed August 2008Phase 2b trials began in May 2009

Insulin SuppositorySuccessful pre-clinical trials

Phase 1 trials in South Africa GLP1-Analog

Pre-clinical trials – Completed 2008Phase 1 trials expected in second half of 2009

Platform drug delivery technology for a variety of peptides

Competitive Landscape

Oral Insulin Capsule:

Diabetology (UK, Phase 2)Emisphere Technologies (US, Phase 2)Biocon (India)

Scientific Advisory Board

Nir Brazilai, MDDirector for the institute of aging research. Member of Diabetes Research Center, Albert Einstein University college of Medicine.

Prof. Ele FerranniniProf. of Internal Medicine, University of Pisa school of Medicine. Professor of Medicine, Diabetes Unit Texas Health science center.

Prof. Avram Herskho, MD, PhDDistinguished Professor in the Biochemistry unit in the B. Rappaport Facility of Medicine in the Technion in Haifa. Nobel Prize Laureate in Chemistry (2004) for the discovery of Ubiquitin- mediated protein degradation.

Derek LeRoith, MDProfessor of Medicine and Chief of Endocrinology, Diabetes and Bone Disease unit, Mount Sinai NY.

Oramed in the news

Oramed’s Oral Insulin Capsule listed as one of the five most promising drugs entering Phase 1 Trials by Thompson Pharma

Chosen from hundreds of companies to represent Israel at the President’s Conference celebrating Israel’s 60th birthday (2008)

Summary

Patent pending technology platform for oral delivery of medications currently delivered via injection

In the pipeline:Oral and rectal delivery of InsulinGLP1-Analog

Strong management team, leading scientific team and clear proof of concept